266 related articles for article (PubMed ID: 11929799)
1. Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants.
Ljungman P; de La Camara R; Milpied N; Volin L; Russell CA; Crisp A; Webster A;
Blood; 2002 Apr; 99(8):3050-6. PubMed ID: 11929799
[TBL] [Abstract][Full Text] [Related]
2. Valacyclovir for the prevention of cytomegalovirus infection after allogeneic stem cell transplantation: a single institution retrospective cohort analysis.
Vusirikala M; Wolff SN; Stein RS; Brandt SJ; Morgan DS; Greer JP; Schuening FG; Dummer JS; Goodman SA
Bone Marrow Transplant; 2001 Aug; 28(3):265-70. PubMed ID: 11535994
[TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy of Antiviral Therapy for Prevention of Cytomegalovirus Reactivation in Immunocompetent Critically Ill Patients: A Randomized Clinical Trial.
Cowley NJ; Owen A; Shiels SC; Millar J; Woolley R; Ives N; Osman H; Moss P; Bion JF
JAMA Intern Med; 2017 Jun; 177(6):774-783. PubMed ID: 28437539
[TBL] [Abstract][Full Text] [Related]
4. Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation.
Winston DJ; Yeager AM; Chandrasekar PH; Snydman DR; Petersen FB; Territo MC;
Clin Infect Dis; 2003 Mar; 36(6):749-58. PubMed ID: 12627359
[TBL] [Abstract][Full Text] [Related]
5. Intragraft cytomegalovirus infection: a randomized trial of valacyclovir prophylaxis versus pre-emptive therapy in renal transplant recipients.
Reischig T; Nemcová J; Vanecek T; Jindra P; Hes O; Bouda M; Treska V
Antivir Ther; 2010; 15(1):23-30. PubMed ID: 20167988
[TBL] [Abstract][Full Text] [Related]
6. Valacyclovir prevention of cytomegalovirus reactivation after heart transplantation: a randomized trial.
Egan JJ; Carroll KB; Yonan N; Woodcock A; Crisp A
J Heart Lung Transplant; 2002 Apr; 21(4):460-6. PubMed ID: 11927223
[TBL] [Abstract][Full Text] [Related]
7. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.
Lowance D; Neumayer HH; Legendre CM; Squifflet JP; Kovarik J; Brennan PJ; Norman D; Mendez R; Keating MR; Coggon GL; Crisp A; Lee IC
N Engl J Med; 1999 May; 340(19):1462-70. PubMed ID: 10320384
[TBL] [Abstract][Full Text] [Related]
8. A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation.
Reischig T; Opatrny K; Bouda M; Treska V; Jindra P; Svecova M
Transpl Int; 2002 Dec; 15(12):615-22. PubMed ID: 12478408
[TBL] [Abstract][Full Text] [Related]
9. A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group.
Feinberg JE; Hurwitz S; Cooper D; Sattler FR; MacGregor RR; Powderly W; Holland GN; Griffiths PD; Pollard RB; Youle M; Gill MJ; Holland FJ; Power ME; Owens S; Coakley D; Fry J; Jacobson MA
J Infect Dis; 1998 Jan; 177(1):48-56. PubMed ID: 9419169
[TBL] [Abstract][Full Text] [Related]
10. Ganciclovir. An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients.
Noble S; Faulds D
Drugs; 1998 Jul; 56(1):115-46. PubMed ID: 9664203
[TBL] [Abstract][Full Text] [Related]
11. Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning.
Kline J; Pollyea DA; Stock W; Artz A; Rich E; Godley L; Zimmerman T; Thompson K; Pursell K; Larson RA; van Besien K
Bone Marrow Transplant; 2006 Feb; 37(3):307-10. PubMed ID: 16400339
[TBL] [Abstract][Full Text] [Related]
12. Prevention of cytomegalovirus infection by valaciclovir after allogeneic bone marrow transplantation from an unrelated donor.
Mori T; Aisa Y; Shimizu T; Nakazato T; Yamazaki R; Ikeda Y; Okamoto S
Int J Hematol; 2006 Apr; 83(3):266-70. PubMed ID: 16720561
[TBL] [Abstract][Full Text] [Related]
13. Valacyclovir prophylaxis for the prevention of Herpes simplex virus reactivation in recipients of progenitor cells transplantation.
Dignani MC; Mykietiuk A; Michelet M; Intile D; Mammana L; Desmery P; Milone G; Pavlovsky S
Bone Marrow Transplant; 2002 Feb; 29(3):263-7. PubMed ID: 11859400
[TBL] [Abstract][Full Text] [Related]
14. Prospective comparison of valacyclovir and oral ganciclovir for prevention of cytomegalovirus disease in high-risk renal transplant recipients.
Reischig T; Opatrný K; Treska V; Mares J; Jindra P; Svecová M
Kidney Blood Press Res; 2005; 28(4):218-25. PubMed ID: 16043964
[TBL] [Abstract][Full Text] [Related]
15. Randomized trial of valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation.
Reischig T; Kacer M; Jindra P; Hes O; Lysak D; Bouda M
Clin J Am Soc Nephrol; 2015 Feb; 10(2):294-304. PubMed ID: 25424991
[TBL] [Abstract][Full Text] [Related]
16. Clinical utility of oral valacyclovir compared with oral acyclovir for the prevention of herpes simplex virus mucositis following autologous bone marrow transplantation or stem cell rescue therapy.
Eisen D; Essell J; Broun ER; Sigmund D; DeVoe M
Bone Marrow Transplant; 2003 Jan; 31(1):51-5. PubMed ID: 12621507
[TBL] [Abstract][Full Text] [Related]
17. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group.
Prentice HG; Gluckman E; Powles RL; Ljungman P; Milpied N; Fernandez Rañada JM; Mandelli F; Kho P; Kennedy L; Bell AR
Lancet; 1994 Mar; 343(8900):749-53. PubMed ID: 7907729
[TBL] [Abstract][Full Text] [Related]
18. A comparative randomised study of valacyclovir vs. oral ganciclovir for cytomegalovirus prophylaxis in renal transplant recipients.
Pavlopoulou ID; Syriopoulou VP; Chelioti H; Daikos GL; Stamatiades D; Kostakis A; Boletis JN
Clin Microbiol Infect; 2005 Sep; 11(9):736-43. PubMed ID: 16104989
[TBL] [Abstract][Full Text] [Related]
19. Comparative study of prophylactic oral ganciclovir and valacyclovir in high-risk kidney transplant recipients.
Yango A; Morrissey P; Zanabli A; Beaulieu J; Shemin D; Dworkin L; Monaco A; Gohh R
Nephrol Dial Transplant; 2003 Apr; 18(4):809-13. PubMed ID: 12637653
[TBL] [Abstract][Full Text] [Related]
20. Low-Dose Valacyclovir for Cytomegalovirus Infection Prophylaxis After a Heart Transplant.
Kervan U; Kucuker SA; Kocabeyoglu SS; Unal EU; Ozatik MA; Sert DE; Kavasoglu K; Tezer AY; Pac M
Exp Clin Transplant; 2016 Oct; 14(5):551-554. PubMed ID: 26976362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
